Search

Displaying results 2591 - 2600 of 10000 in total
  1. Drug

    ST266

    go.drugbank.com/drugs/DB18614
    Investigational

    ST266 is an amniotic membrane-derived cellular cytokine solution.

  2. Drug

    VGB-R04

    go.drugbank.com/drugs/DB18615
    Investigational

    VGB-R04 is an adeno-associated viral vector delivering human FIX Padua gene.

  3. Drug

    AAV9/MFSD8

    go.drugbank.com/drugs/DB18616
    Experimental

    AAV9/MFSD8 is a gene therapy developed by Neurogene Inc. … It is an adeno-associated virus serotype 9 (AAV9) vector with an engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8

    Synonyms: An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8
  4. Drug

    WU-CART-007

    go.drugbank.com/drugs/DB18617
    Investigational

    WU-CART-007 consists of allogeneic, fratricide-resistant genetically modified T cells transduced with a 2nd generation 4-1BB-CD3z chimeric antigen receptor targeting human CD7.

    Synonyms: an allogeneic, fratricide-resistant genetically modified T cell transduced with a 2nd generation 4-1BB-CD3z chimeric antigen receptor targeting human CD7
  5. Drug

    Prizloncabtagene autoleucel

    go.drugbank.com/drugs/DB18623
    Investigational

    C-CAR039 is an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR.

    Synonyms: autologous T lymphocytes obtained from peripheral blood lymphocytes by leukapheresis, transduced with a self-inactivating, non-replicating lentiviral vector, encoding a bispecific chimeric antigen receptor, an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR
  6. Drug

    VOR33

    go.drugbank.com/drugs/DB18624
    Investigational

    VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 protein.

  7. Drug

    CTX120

    go.drugbank.com/drugs/DB18625
    Investigational

    CTX120 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting B-cell maturation antigen.

    Synonyms: allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting B-cell maturation antigen
  8. Drug

    CTX110

    go.drugbank.com/drugs/DB18626
    Investigational

    CTX110 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD19 antigen.

    Synonyms: allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting CD19 antigen
  9. Drug

    Myrtecaine

    go.drugbank.com/drugs/DB15785
    Investigational

    Mixtures: Algesal 10 %/1 % - Creme, ALGESAL SURACTİVE %10 + %1 MERHEM, 40 GR
  10. Drug

    AZD7442

    go.drugbank.com/drugs/DB15787
    Investigational

    AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. … [L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.[L15591]